The estimated Net Worth of Robert E Mcnamara is at least $1.57 Milion dollars as of 13 January 2021. Mr. Mcnamara owns over 9,167 units of Axonics Inc stock worth over $515,475 and over the last 6 years he sold AXNX stock worth over $475,126. In addition, he makes $577,081 as Independent Director at Axonics Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. McNamara AXNX stock SEC Form 4 insiders trading
Robert has made over 1 trades of the Axonics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 9,167 units of AXNX stock worth $475,126 on 13 January 2021.
The largest trade he's ever made was selling 9,167 units of Axonics Inc stock on 13 January 2021 worth over $475,126. On average, Robert trades about 1,833 units every 0 days since 2018. As of 13 January 2021 he still owns at least 7,500 units of Axonics Inc stock.
You can see the complete history of Mr. Mcnamara stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert McNamara biography
Robert E. McNamara serves as Independent Director of the Company. Since February 2018, Mr. McNamara has served as a member of the board of directors and audit committee of Xtant Medical Holdings, Inc. (OTCMKTS: XTNTW), a publicly traded manufacturer and marketer of regenerative medical products and devices. Mr. McNamara previously worked at LDR Holdings/Spine, Inc., serving as its Executive Vice President from January 2013 to July 2016, and serving as its Chief Financial Officer from April 2012 to July 2016. From 2006 to 2009, Mr. McNamara served as a member of the board of directors and audit committee of Northstar Neurosciences, a publicly traded medical device company. From December 2004 to September 2008, Mr. McNamara was the Senior Vice President and Chief Financial Officer of Accuray, Inc., a publicly traded medical device manufacturer. In addition, Mr. McNamara has served as the Senior Vice President and Chief Financial Officer of Somnus Medical Technologies and the Chief Financial Officer for Target Therapeutics, Inc., each publicly traded companies. Mr. McNamara is the former Mayor of Menlo Park, California. Mr. McNamara holds a B.S. in Accounting from the University of San Francisco and an M.B.A. in Finance from The Wharton School of Business.
What is the salary of Robert McNamara?
As the Independent Director of Axonics Inc, the total compensation of Robert McNamara at Axonics Inc is $577,081. There are 7 executives at Axonics Inc getting paid more, with Raymond Cohen having the highest compensation of $6,147,640.
How old is Robert McNamara?
Robert McNamara is 63, he's been the Independent Director of Axonics Inc since 2018. There are 2 older and 20 younger executives at Axonics Inc. The oldest executive at Axonics Inc is Nancy Snyderman, 68, who is the Independent Director.
What's Robert McNamara's mailing address?
Robert's mailing address filed with the SEC is 26, Technology Drive, Irvine Spectrum, Irvine, Orange County, California, 92618, United States.
Insiders trading at Axonics Inc
Over the last 6 years, insiders at Axonics Inc have traded over $108,010,643 worth of Axonics Inc stock and bought 4,672,163 units worth $70,180,620 . The most active insiders traders include Asset Management, Lp Chen B..., Shahzad Malik a Geoff Pardo. On average, Axonics Inc executives and independent directors trade stock every 15 days with the average trade being worth of $4,280,711. The most recent stock trade was executed by Raymond W Cohen on 24 July 2024, trading 103,896 units of AXNX stock currently worth $2,383,374.
What does Axonics Inc do?
axonics modulation technologies, inc is a privately-held medical device company developing an innovative neuromodulation platform based on a miniaturized rechargeable fully-implantable ipg licensed from the alfred mann foundation. the axonics sacral neuromodulation system is designed to improve the experience of both clinicians and patients suffering from urinary and fecal dysfunction.
What does Axonics Inc's logo look like?
Complete history of Mr. Mcnamara stock trades at Axonics Inc
Axonics Inc executives and stock owners
Axonics Inc executives and other stock owners filed with the SEC include:
-
Raymond Cohen,
Chief Executive Officer, Director -
Dan Dearen,
President, Chief Financial Officer -
Rinda Sama,
Chief Operating Officer -
Raymond W. Cohen,
CEO & Director -
Danny L. Dearen,
Pres & CFO -
Dr. Karen L. Noblett M.D., M.A.S.,
Chief Medical Officer -
Rinda K. Sama,
Chief Operating Officer -
Robert McNamara,
Independent Director -
Juliet Tammenoms Bakker,
Independent Director -
Alfred J. Ford Jr.,
Chief Commercial Officer -
Erik Amble,
Independent Director -
Michael Carrel,
Independent Chairman of the Board -
Jane Kiernan,
Independent Director -
Nancy Snyderman,
Independent Director -
Karen Noblett,
Chief Medical Officer -
Prabodh Mathur,
Chief Product Development Officer -
Alfred Ford,
Chief Commercial Officer -
John Woock,
Chief Marketing Officer -
Dr. Karen L. Noblett M.A.S., M.D.,
Chief Medical Officer -
Michael V. Williamson Esq., J.D.,
Sr. VP, Gen. & IP Counsel -
Michael V. Williamson,
Sr. VP, Gen. & IP Counsel -
Dr. John Woock Ph.D.,
Exec. VP, Chief Marketing & Strategy Officer -
Aaron Pettit,
Gen. Counsel & Chief Compliance Officer -
Neil Bhalodkar,
VP of Investor Relations -
Guangqiang Jiang Ph.D.,
Chief Technology Officer -
Esteban Lopez,
-
John George Petrovich,
Director -
Shahzad Malik,
Director -
Life Sciences Llp Advent Li...,
-
Partners Bio Discovery 4 Fc...,
-
E. Mann Foundation For Scie...,
-
Capital Partners Iii, Llcen...,
-
Innovation V Ltd Neo Med In...,
-
Healthcare Holding B.V.Gild...,
-
Asset Management, Lp Chen B...,
-
Michael V. Williamson,
SVP, General Counsel -
Guangqiang Jiang,
Chief Technology Officer -
Zhong Zac & Cloud Holdings ...,
-
Raphael Wisniewski,
-
Robert E Mcnamara,
-
Geoff Pardo,
-
David M Demski,
-
Kari Leigh Keese,
Chief Financial Officer